These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 35314843)

  • 1. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.
    Narayan V; Barber-Rotenberg JS; Jung IY; Lacey SF; Rech AJ; Davis MM; Hwang WT; Lal P; Carpenter EL; Maude SL; Plesa G; Vapiwala N; Chew A; Moniak M; Sebro RA; Farwell MD; Marshall A; Gilmore J; Lledo L; Dengel K; Church SE; Hether TD; Xu J; Gohil M; Buckingham TH; Yee SS; Gonzalez VE; Kulikovskaya I; Chen F; Tian L; Tien K; Gladney W; Nobles CL; Raymond HE; ; Hexner EO; Siegel DL; Bushman FD; June CH; Fraietta JA; Haas NB
    Nat Med; 2022 Apr; 28(4):724-734. PubMed ID: 35314843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
    Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
    Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial.
    Dorff TB; Blanchard MS; Adkins LN; Luebbert L; Leggett N; Shishido SN; Macias A; Del Real MM; Dhapola G; Egelston C; Murad JP; Rosa R; Paul J; Chaudhry A; Martirosyan H; Gerdts E; Wagner JR; Stiller T; Tilakawardane D; Pal S; Martinez C; Reiter RE; Budde LE; D'Apuzzo M; Kuhn P; Pachter L; Forman SJ; Priceman SJ
    Nat Med; 2024 Jun; 30(6):1636-1644. PubMed ID: 38867077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy.
    Lindo L; Wilkinson LH; Hay KA
    Front Immunol; 2020; 11():618387. PubMed ID: 33643299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SMAD7 expression in CAR-T cells improves persistence and safety for solid tumors.
    Liang S; Zheng R; Zuo B; Li J; Wang Y; Han Y; Dong H; Zhao X; Zhang Y; Wang P; Meng R; Jia L; Yang A; Yan B
    Cell Mol Immunol; 2024 Mar; 21(3):213-226. PubMed ID: 38177245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current Trend of CAR-T Cell Therapy for Metastatic Castration-Resistant Prostate Cancer].
    Takahashi S
    Gan To Kagaku Ryoho; 2023 Oct; 50(10):1038-1042. PubMed ID: 38035830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer.
    Zanvit P; van Dyk D; Fazenbaker C; McGlinchey K; Luo W; Pezold JM; Meekin J; Chang CY; Carrasco RA; Breen S; Cheung CS; Endlich-Frazier A; Clark B; Chu NJ; Vantellini A; Martin PL; Hoover CE; Riley K; Sweet SM; Chain D; Kim YJ; Tu E; Harder N; Phipps S; Damschroder M; Gilbreth RN; Cobbold M; Moody G; Bosco EE
    J Clin Invest; 2023 Nov; 133(22):. PubMed ID: 37966111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Armored bicistronic CAR T cells with dominant-negative TGF-β receptor II to overcome resistance in glioblastoma.
    Li N; Rodriguez JL; Yin Y; Logun MT; Zhang L; Yu S; Hicks KA; Zhang JV; Zhang L; Xie C; Wang J; Wang T; Xu J; Fraietta JA; Binder ZA; Lin Z; O'Rourke DM
    Mol Ther; 2024 Oct; 32(10):3522-3538. PubMed ID: 39086131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication.
    Kloss CC; Lee J; Zhang A; Chen F; Melenhorst JJ; Lacey SF; Maus MV; Fraietta JA; Zhao Y; June CH
    Mol Ther; 2018 Jul; 26(7):1855-1866. PubMed ID: 29807781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1.
    Tran TM; Chand Thakuri BK; Nurmukhambetova S; Lee JJ; Hu P; Tran NQ; Steimle B; Dash P; Schneider D
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38609317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-13Rα2/TGF-β bispecific CAR-T cells counter TGF-β-mediated immune suppression and potentiate anti-tumor responses in glioblastoma.
    Hou AJ; Shih RM; Uy BR; Shafer A; Chang ZL; Comin-Anduix B; Guemes M; Galic Z; Phyu S; Okada H; Grausam KB; Breunig JJ; Brown CE; Nathanson DA; Prins RM; Chen YY
    Neuro Oncol; 2024 Oct; 26(10):1850-1866. PubMed ID: 38982561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer.
    Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Modarressi MH; Abolhassani M
    J Cell Biochem; 2019 Jun; 120(6):10787-10795. PubMed ID: 30672018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-β.
    Alabanza LM; Xiong Y; Vu B; Webster B; Wu D; Hu P; Zhu Z; Dropulic B; Dash P; Schneider D
    Front Immunol; 2022; 13():832645. PubMed ID: 35222421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma.
    Qu X; An G; Sui W; Wang T; Zhang X; Yang J; Zhang Y; Zhang L; Zhu D; Huang J; Zhu S; Yao X; Li J; Zheng C; Zhu K; Wei Y; Lv X; Lan L; Yao Y; Zhou D; Lu P; Qiu L; Li J
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36100310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial.
    Brown CE; Hibbard JC; Alizadeh D; Blanchard MS; Natri HM; Wang D; Ostberg JR; Aguilar B; Wagner JR; Paul JA; Starr R; Wong RA; Chen W; Shulkin N; Aftabizadeh M; Filippov A; Chaudhry A; Ressler JA; Kilpatrick J; Myers-McNamara P; Chen M; Wang LD; Rockne RC; Georges J; Portnow J; Barish ME; D'Apuzzo M; Banovich NE; Forman SJ; Badie B
    Nat Med; 2024 Apr; 30(4):1001-1012. PubMed ID: 38454126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression.
    Weimin S; Abula A; Qianghong D; Wenguang W
    Cancer Biol Ther; 2020 Jun; 21(6):570-580. PubMed ID: 32208880
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
    Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A
    Cells; 2020 Jun; 9(6):. PubMed ID: 32498368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-throughput method to analyze the cytotoxicity of CAR-T Cells in a 3D tumor spheroid model using image cytometry.
    Zurowski D; Patel S; Hui D; Ka M; Hernandez C; Love AC; Lin B; Moore A; Chan LL
    SLAS Discov; 2023 Apr; 28(3):65-72. PubMed ID: 36758833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. INSPIRED Symposium Part 5: Expanding the Use of CAR T Cells in Children and Young Adults.
    Talleur AC; Fabrizio VA; Aplenc R; Grupp SA; Mackall C; Majzner R; Nguyen R; Rouce R; Moskop A; McNerney KO
    Transplant Cell Ther; 2024 Jun; 30(6):565-579. PubMed ID: 38588880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Research Progress on the Influence of Blood Tumor Microen-vironment on the Efficacy and the Adverse Reactions of CAR-T Cell Immunotherapy--Review].
    Liao CF; Lai HR; Li J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Aug; 32(4):1290-1294. PubMed ID: 39192433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.